CURRICULUM VITAE

MICHAEL P. RIVEY

Address: 6015 Sunview Dr.Telephone: 406-251-3369(home)

Missoula, MT 59801 406-243-6796(work)

PROFESSIONAL GOALS

1.Involvement in development and execution of clinical pharmacy services.

2.Participation in design and implementation of educational services to provide current medical information concerning drug therapy.

3.Participation in the investigation and documentation of issues in health care relating to pharmacy.

EDUCATION

Master of Science in Pharmacy, Clinical and Hospital Pharmacy Division, University of Iowa, December 1982. Thesis committee: Mary J. Berg, Pharm.D., Boris A. Vern, M.D., Richard Leff, Pharm.D.

Courses: advanced therapeutics, biostatistics, clinical toxicology, epidemiology, advanced pharmacokinetics and biopharmaceutics, clinical pharmacokinetics, research methods, advanced neurology, antimicrobials, nuclear pharmacy, and thesis research.

Bachelor of Science in Pharmacy, University of Iowa, May 1974.

PROFESSIONAL EXPERIENCE

Professor, July 1998 to present.

* Chair of Pharmacy Practice: November 2003 to present

Associate Professor, July 1991 to 1998

Assistant Professor, July 1984 to 1991, School of Pharmacy, University of Montana, Missoula, Montana.

Dean: David Forbes, Ph.D.

1.Instructor for clinical pharmacy curriculum, including Therapeutics Sequence, and other practice-related courses.

a. Focus areas: internal medicine, anticoagulation, infectious disease

2.Residency Program Director for PGY1 residency in Pharmacy Practice

2.Direction of senior students during clinical clerkship and hospital externship at Community Medical Center, Missoula, Mt.

3.Instruction in courses for Psychology graduate students, Physical Therapy students, and Nurse Practitioner students.

4.Instruction of Pharm.D. students in distance-learning external Pharm.D. program.

Clinical Consultant and Residency Program Director, April 2004 to present. Community Medical Center, Missoula, Montana.

Consultant to clinical pharmacy services in 145-bed hospital. Manager of pharmacokinetics service. Residency Program Director for pharmacy practice residency jointly sponsored by CMC and UM, and primary preceptor for that program at CMC.

Michael P. Rivey, CVPage 2

PROFESSIONAL EXPERIENCE (continued):

Clinical Coordinator, December 1984 to April 2004, Community Medical Center, Missoula, Montana.

Coordinator for clinical pharmacy services in 145-bed community hospital. Responsible for clinical program development, drug utilization review including antibiotic review, pharmacokinetic service, drug therapy monitoring service and drug information. Residency Program Director since 2001. Member of P&T, Infection Control, Physician QI, and Diabetes Task Force Committees.

Assistant Clinical Instructor, February 1984 to May 1984, University of Iowa, Iowa City, Iowa.

Instructor of clinical pharmacy clerkship in adult medicine for senior pharmacy students at Veterans Administration Hospital. Maintained clinical practice in pulmonary medicine ward and assisted with clinical nutrition team.

Clinical Pharmacy Resident (ASHP approved), January 1983 to December 1983, Veterans Administration Medical Center, Iowa City, Iowa.

Preceptors: Michael R. Alexander, M.S. and Alan Mustion, B.S.

1.Pulmonary medicine, under supervision of Michael R. Alexander, M.S., 2 months service on medical ward team; responsibilities of team included medical intensive care unit.

2.Internal medicine, under supervision of Jerry W. Taylor, Pharm.D. and Michael R. Alexander, M.S., 4 months.

3.Psychiatric service, under supervision of Bruce Alexander, Pharm.D. 2 months.

4.Clinical pharmacokinetics service, under supervision of Randall A. Prince, Pharm.D., 2 months.

5.Administrative practice and projects, under supervision of Alan Mustion, B.S., 2 months.

6.Clinical pharmacist in outpatient pulmonary clinic, 12 months.

7.Participation in undergraduate and Pharm.D. student teaching, 9 months.

8.Development of technician training lecture course.

9.Assistance with clinical research projects.

10.Inspection of pharmacy services at Quincy Soldiers Home.

11.Presentations to medical staff and students during staffing rounds.

12.Participation with Total Parenteral Nutrition team.

Teaching Assistant, September 1980 to July 1982, Iowa Drug Information Service (IDIS), University of Iowa, Iowa City, Iowa.

Indexed medical literature into computer-based drug information system and handled drug information requests from subscribers.

Staff Pharmacist, July 1974 to August 1980. various settings and locations.

Provided services to wide spectrum of pharmacy operations including clinic, community, and hospital pharmacies.

Michael P. Rivey, CVPage 3

PROFESSIONAL EXPERIENCE (continued):

Pharmacy Manager, April 1977 to March 1978, Cal-Meds, Inc., Hayward, California.

Provided unit dose pharmacy services to skilled nursing facilities in San Francisco bay area; involvement in therapy consultation and review, and nursing inservice education. Preceptor

to clinical rotation for senior students from University of Pacific College of Pharmacy.

Pharmacy Intern and Staff, September 1974 to May 1975, Mohave General Hospital, Kingman, Arizona.

Provided inpatient and outpatient pharmacy services, comprehensive IV admixture program, and nursing inservice education. Member of CPR team and Pharmacy and Therapeutics Committee.

PUBLICATIONS

Tietje TM, Davis AB, Rivey MP. Comparison of two methods of local anesthetic-based injection as

partof a multimodal approach to pain management after total knee arthoplasty. J Pharm Practice 2014.Accepted for publication June 2014.

Aikens GB, Osmundson JR, Rivey MP. New oral pharmacotherapeutic agents for venous

thromboprophylaxis after total hip arthroplasty. World J Orthop2014; 5:188-203. Invited review. Published online July 2014.

Rivey MP, Allington DR. Gastrointestinal Infections with Enterotoxigenic Bacterium. Cases 146 &

147. ASHP’s PharmPrep 5th Edition, Ginsburg DB, editor, American Society of Health-

SystemPharmacists, Bethesda, MD. 2013. Accepted for publication.

Allington DR, Rivey MP. Multiple sclerosis (MS) in a primary care setting: Employing strategies

for improved patient outcomes. Invited continuing education (CE) program for ScientiaCME. Program included Powerpoint slide set with audio presentation, CE post-test questions, and recommendation for future program. Nov 2013.

Tietje TM, Allington DR, Rivey MP. Alemtuzumab: A place in therapy for multiple sclerosis.

Int JClin Med 2013;4:459-71. Published online October 2013

Allington DR, Davis A, Sutton J, Rivey MP. Multiple Sclerosis: Fundamental concepts and clinical

perspectives. Book chapter 22 for Advances in Viral Research II. iConcept Press LTD.

ISBN: 978-1477555-04-0.Sept 2013.

Aikens GB, Rivey MP, Hansen CJ. Primary venous thromboembolism prophylaxis in ambulatory

cancer patients. Ann Pharmacother 2013;47:198-209. Published online February 5, 2013.

doi 10.1345/aph.1R335

Nwankwo E, Allington DR, Rivey MP. Emerging oral immunomodulating agents- focus on

teriflunomide for the treatment of multiple sclerosis. Degenerative Neurological and Neuromuscular Disease 2012; 2:15-28.

Michael P. Rivey, CVPage 4

Publications (continued):

Summerday NM, Brown SJ, Allington D, Rivey MP. Vitamin D and Multiple Sclerosis: Review of a

possible association. J Pharm Practice 2012:25:75-84. e-publication in October 2011.

doi: 10.1177/0897190011421839

Rivey MP. Anticoagulation Therapy: A Point-of-Care Guide (book review). Ann Pharmacother

2011; 45:1034-5. Published online July 5, 2011. DOI 10.1345/aph.1Q188

Rivey MP. Pharmacotherapy Principles & Practice, 2nd edition (book review). Ann Pharmacother

2010; 44: 2042. Published online Nov 23, 2010. DOI10.1345/aph.1P485

Barten LJ, Allington DR, Procacci KA, Rivey MP. New approaches in the management of multiple

sclerosis. Drug Design, Development and Therapy 2010:4:1-23.

Rivey MP, Allington DR. Gastrointestinal Infections with Enterotoxigenic Bacterium. Cases 146 &

147. ASHP’s PharmPrep 4th Edition, Ginsburg DB, editor, American Society of Health

SystemPharmacists, Bethesda, MD. 2010. Published as online cases.

Barten LJ, Allington DR, Procacci KA, Rivey MP. Natalizumab update: a story of benefit and

risk. Drug Discovery Today: Therapeutic Strategies 2009. DOI 10.1016/j.ddstr.2009.10.002

Korenke AR, Rivey MP, Allington DR. Sustained-release fampridine for symptomatic treatment of

multiple sclerosis. Ann Pharmacother 2008;42:1458-65

Rivey MP, Allington DR. Gastrointestinal Infections. Cases 146 & 147. ASHP’s PharmPrep 3rd

Edition, Ginsburg DB, editor, American Society of Health SystemPharmacists, Bethesda,

MD. 2007.

Allington DR, Rivey MP. Gastrointestinal infections. Case 147. ASHP’s PharmPrep 3rd Edition,

Ginsburg DB, editor, American Society of Health SystemPharmacists, Bethesda, MD. 2007.

Patrick BN, Rivey MP, Allington DR. Acute renal failure associated with vancomycin- and

tobramycin-laden cement in total hip arthroplasty. Ann Pharmacother 2006;40:2037-42.

Colucci VJ and Rivey MP. Potential contribution of long-term rofecoxib in a patient with

cardiogenic syncope and ischemic stroke. J PharmTechnol 2006;22:174-8.

Keeley KA, Rivey MP, Allington DR. Natalizumab in the treatment of multiple sclerosis and

Crohn’s disease. Ann Pharmacother 2005;39:1833-43.

Rivey MP, Allington DR, Mathis JB. Evaluation of a risk assessment approach to venous

thromboembolism (VTE) prophylaxis in medically ill patients. Pharmacotherapy

2005;25:1502(abstract).

Michael P. Rivey, CVPage 5

Publications (continued):

Brophy DF, Dougherty JA, Garrelts JC, Parish RC, Rivey MP, Stumpf JL, Taylor CT, Mathis AS.

Venous thromboembolism prevention in acutely ill nonsurgical patients. AnnPharmacother

2005;39:1318-24.

Keeley KA, Mathis JB, Rivey MP. Medication Reconciliation in Hospitalized Patients. The New

Montana Pharmacist 2005; summer issue: pp 6-7. (nonrefereed)

Rivey MP, Allington DR. Gastrointestinal infections with enterotoxigenic bacterium.

Cases 146. pp 96-98. ASHP’s PharmPrep 2nd Edition, Ginsburg DB, editor, American Society of Health System Pharmacists, Bethesda, MD. 2004

Rivey MP, Allington DR. Gastrointestinal infections with enterotoxigenic bacterium.

Cases 147. CD medium. ASHP’s PharmPrep 2nd Edition, Ginsburg DB, editor, American Society of Health System Pharmacists, Bethesda, MD. 2004

Rivey MP, Beall HD, Woolley D, Brand P, Ganser A, James W. Investigation of intraarticular

bupivacaine in major orthopedic surgery for postoperative pain control. Pharmacotherapy

2001;21:366-7 (abstract).

Allington DR, Rivey MP. Quinupristin/dalforpristin: A therapeutic review. ClinTher 2001;23:

24-44.

Struckman DR, Rivey MP. Combined therapy with an angiotensin II receptor blocker and an

angiotensin-converting enzyme inhibitor in heart failure. Ann Pharmacother 2001;35:

242-8.

McHugh M, Allington DR, Rivey MP. Combination aspirin and dipyridamole & secondary stroke

prevetion. Montana Pharmacist 2000;24(No.3):6-7. (not refereed)

Carter JT, Allington DR, Rivey MP. Medical rehabilitation clerkship experience for Pharm.D.

students. Am J PharmEduc 2000;64:96S (abstract).

Colucci VJ, Rivey MP. Tolterodine-warfarin drug interaction. Ann Pharmacother 1999;33:1173-6.

Messer KG, Rivey MP. Feasibility study for pharmacist-directed asthma management in a pediatric practice. Pharmacotherapy 1999;19:521 (abstract).

Rivey MP, Allington DR, Henry Dunham AL. Necrotizing fasciitis associated with nonsteroidalantiinflammatory drug use. J PharmTechnol 1998;14:58-62.

Rivey MP. Pharmacist-managed drug therapy protocols at CommunityMedicalCenter. MSHP Newsletter 1997;6(No.3):3-5. (not refereed)

Stone JD, Rivey MP, Allington DR. Nitroprusside treatment of erythromelalgia in an adolescent female. Ann Pharmacother 1997;31:590-2.

Michael P. Rivey, CVPage 6

Publications (continued):

Rivey MP, Wood RD, Allington DR, Stratton TP, Erickson CC, Stenson TA. Pharmacy-managed protocol for warfarin use in orthopedic surgery patients. Am J Health-SystPharm 1995;52:1310-6.

Rivey MP, Allington DR, Stone JD, Serfoss ML. Alteration of carbamazepine pharmacokinetics in patients with traumatic brain injury. Brain Injury 1995;9:41-7.

Allington DR, Rivey MP. Multiple Sclerosis: An overview. American Pharmacy 1994, accepted for publication, but never published.

Rivey MP, Wood RD, Allington DR, Erickson CC. Evaluation of CoumadinR Protocol in Orthopedic Surgery Patients. Pharmacotherapy 1993;13:272 (abstract). Report in HospFormulary Oct 1993.

Rivey MP and Peterson JP. Pharmacy-managed, weight-based heparin protocol in a small hospital. Am J Hosp Pharm 1993;50:279-84. Report in Clinical Digest Series

Rivey MP, Allington DR, Stone JD. Evidence for alteration of carbamazepine pharmacokinetics during chronic therapy in patients with closed head injury. Pharmacotherapy 1992;12:505 (abstract). Report in CA/CTF.

Rivey MP, North GL, Harper DA, Cochran TG, Simmerman J. Evolution of a neonatal gentamicin dosing protocol in a small community hospital. J Perinatol 1992;12:346-53.

Rivey MP. Hepatitis: A viral alphabet. Montana Pharmacist 1992; 15(3):15-7 (not refereed)

Rivey MP and Stone JD. Carbamazepine hypersensitivity reaction. Brain Injury 1991;5:57-62.

Rivey MP and Peterson JP. Intradermal hepatitis B vaccination. DICP Ann Pharmacother 1991; 25:628-34.

Rivey MP. The School of Pharmacy self-study: What was it, and what did it say? Montana Pharmacist 1991;14:17-9. (not refereed)

Rivey MP. Psychotropic medication and falls in the elderly. Montana Pharmacist 1991;14:24-6. (not refereed)

Rivey MP, Morin LJ, Haakenson P. Attitudes of first-year pharmacystudents and preceptors to a "mini-externship" in hospital and community pharmacy practice. Am J PharmEduc 1990;54:146-9.

Rivey MP. Warfarin: New developments for an old drug. Montana Pharmacist 1990;13(1);11-4. (not refereed)

Michael P. Rivey, CVPage 7

Publications (continued):

Freeman D, Cochran G, Rivey M. Search for alterations in red blood cell enzymes in Alzheimer's Disease (abstract). ProcMontAcadSci 1989;49:165.

Rivey MP, Taylor JW, and Mullenix TA. TMP/SMX in renally-impaired patients with P. carinii pneumonia. Drug IntellClinPharm 1989;23:687-9.

Rivey MP. The use of technicians in pharmacy: A present perspective. Montana Pharmacist 1988;11:7-8,14. (not refereed)

Berg MJ, Ebert BE, Rivey NP, and Schottelius DD. Utilization of Km for phenytoin dosage after folate addition to patient regimen. Ther Drug Monitor 1987;9:304-305.

Rivey MP, Docktor WJ, and Winship MJ. Aminoglycoside monitoring in the neonate. Drug IntellClinPharm 1985;19:908-909.

Taylor JW, Murphy MJ, and Rivey MP. Clinical and electrophysiological evaluation of peripheral nerve function in chronic phenytoin therapy. Epilepsia 1985;26:416-420.

Rivey MP, Alexander MR, and Taylor JW. Dipyridamole: A critical evaluation. Drug IntellClin

Pharm 1984;18:869-880.

Taylor JW, Alexander B, Kathol RG, Alexander MR, Ebert B, and Rivey MP. Pharmacokinetic analysis of phenytoin-disulfiram interaction (abstract). Drug IntellClinPharm 1984;18:499.

Rivey MP, Schottelius DD, and Berg MJ. Phenytoin-folic acid: A review. Drug IntellClinPharm 1984;18:292-301.

Berg MJ, Rivey MP, Vern BA, Fischer LJ, and Schottelius DD. Phenytoin and folic acid: Individualized drug interaction. Ther Drug Monitor 1983;5:389-394.

Berg, MF, Fischer LJ, Rivey MP, Vern VA, and Schottelius DD. Phenytoin and folic acid interaction: A preliminary report. Ther Drug Monitor 1983;5:389-394.

Rivey MP. The Effect of Folic Acid Supplementation on Phenytoin Pharmacokinetics in Seizure Patients. Thesis, University of Iowa, December 1982.

POSTERS/PRESENTATIONS AT NATIONAL & STATE PROFESSIONAL MEETINGS

Rivey MP, Faul M, Chong C, Carter J. Vancomycin pharmacokinetics changes with prolonged

therapy. Poster presented to Northwest Pharmacy Convention, Coeur d’ alene, ID. May 2014

Michael P. Rivey, CVPage 8

Posters/Presentations at National & State Professional Meetings (continued):

Chong C, Rivey M, Allington D, Cady K. Quality assessment of inpatient managed anticoagulation

protocol. Poster presented to ASHP Midyear Clinical Meeting, Orlando, FL. December 2013.

Davis A, Tietje T, Roestenburg S, Rivey M, James W, Cady K. Comparison of intraoperative

injections for sustained analgesia after total knee arthroplasty. Poster presentation to

Northwest Pharmacy Convention, Coeur d’ alene, ID. May 2013

Davis A, Tietje T, Roestenburg S, Rivey M, James W, Cady K. Comparison of intraoperative

injections for sustained analgesia after total knee arthroplasty. Poster presentation to

ASHP Midyear Clinical Meeting, Las Vegas, NV. December 2012

Rivey MP, Carter JT, Docktor WJ, Allington DR. Incorporating pharmacy practice faculty

attributesinto a university-affiliated PGY1 residency. Poster presentation to L.S. Skaggs

Biomedical Research Symposium, Denver, CO. September 2012.

Summerday NM, Lyons D, Rivey MP, Cady K. Vancomycin dosing: A review of the efficacy of

pharmacist dosing protocol. Poster presentation to ASHP Midyear Clinical Meeting,

Anaheim, CA. December 2010.

Barten L, Rivey MP. Implementation of an asthma discharge protocol in a hospital emergency

department. Platform presentation to Western States Conference for Residents, Monterey,

CA. May 2010

Rivey MP. Osteoarthritis Rx Update. Presentation to Montana Gerontology Society Annual

Conference, Missoula, MT. April 2010

Byrd A, Rivey MP. Presciption drug abuse committee addresses concerns of deaths related to

prescription abuse. A review of stored unused medications and disposal. Platform

presentation to Western States Conference for Residents, Monterey, CA. May 2009

Korenke A, Rivey M, Hightower L, Cady K. Osteoporosis screening in a community medical

center. Platform presentation to Western States Conference for Residents, Monterey, CA.

May 2008

Johnson KM, Rivey MP, Mathis JB. ICU clinical pharmacy services in small hospitals: A

feasibility study. Platform presentation to Western States Conference for Residents, Monterey, CA. May 2007

Patrick B, Rivey M, Mathis JB. Lipid management in at risk patients. Platform presentation to

Western States Conference for Residents, Monterey, CA. May 2006

Patrick BN, Rivey MP, Allington DR, Mathis B. Lipid management in at-risk patients. Poster

presented to 40th ASHP Midyear Meeting. LasVegas. December 2005

Michael P. Rivey, CVPage 9

Posters/Presentations at National & State Professional Meetings (continued):

Rivey MP, Allington DR, Mathis JB. Evaluation of a risk assessment approach to venous

thromboembolism (VTE) prophylaxis in medically ill patients. Poster (refereed) presented

to ACCP Annual Meeting, San Francisco, CA. October 2005.

Rivey MP. Anticoagulation in the orthopaedic patient. Presentation to Second Annual Montana

Orthopaedic Conference, Missoula, MT. September 2005.

Rivey MP. NSAIDs Update. Presentation to Second Annual MontanaOrthopaedic Conference,

Missoula, MT. September 2005.

Rivey MP. Update on Prevention of Venous Thromboembolism. Presented to NorthValley

Hospital Grand Rounds, Whitefish, MT. February 2005. Sponsored by Aventis, Inc.

Rivey MP. Update on Prevention of Venous Thromboembolism. Presented to Community Medical

Center CE Education Series, Missoula, MT. January 2005. Sponsored by Aventis, Inc.

Keeley K, Rivey M, Allington D, Mathis B. Pharmacist-conducted medication histories. Poster

presented to ASHP Midyear Clinical Meeting, Orlando, Fl. December 2004.

Rivey MP. Update: Prevention and Treatment of Thrombosis. Presentation to Montana Pharmacy

Association (MPA) Fall Meeting, Whitefish, MT. October 2004. 2 hours.

Rivey MP and Gong WC. Training Residents in Self-Evaluation. Invited presentation to 2004

ASHP National Residency Preceptors Conference. Presented two 1.5 hr sessions. San Diego,

CA. August 2004

Hunt K and Rivey MP. Evaluation of venous thromboembolism (VTE) prophylaxis in surgical and

hospitalized patients. Poster (refereed) presented to ASHP Western States Residency

Conference, Monterey, CA, May 2004.

Rivey MP, Hunt KM, Allington DR. Evaluation of thrombosis risk assessment in surgical patients.

Poster (refereed) presented to 2nd ACCP-ESCP International Congress on Clinical

Pharmacy, Paris, France, April 29, 2004

Rivey MP, Allington DR, Reinivaara-Hall T, Mathis JB, Miller DC, McKernan JL. Development

of a Pharmacy Practice residency with a focus in pain management in a small hospital. Poster presented at American Society of Health-Systems Pharmacists (ASHP) Midyear Clinical Meeting, New Orleans, LA, December 2003.

Hunt K, Rivey MP. Evaluation of venous thromboembolism prophylaxis in surgical patients after

the implementation of a Thrombosis Risk Assessment sheet. Poster presented to ASHP Midyear Clinical Meeting, New Orleans, LA, December 2003.

Michael P. Rivey, CVPage 10

Posters/Presentations at National & State Professional Meetings (continued):

Carter JT, Allington DR, Rivey MP. Use of concept maps to assess clerkship students’ knowledge

of stroke. Poster presented at American Association of Colleges of Pharmacy (AACP) Annual Meeting, Minneapolis, MN, July 2003.

Carter JT, Miller SJ, Rivey MP. Student performance on negatively versus positively worded

multiple choice questions in a Therapeutics course. Poster presented at AACP Annual

Meeting, Kansas City, MO, July 2002.

Miller DC, Rivey MP, James W, et al. Effect of non-narcotic analgesics on post-operative use of

narcotics and antiemetics following major orthopedic surgery. Presented at ASHP Clinical

Midyear Meeting, New Orleans, LA, December 2001.

Rivey MP. New drug developments and new indications for existing drugs. Presentation to

Montana Pharmacy Association (MPA) Fall Meeting, Lewistown, MT, September 2001.

Cochran TG, Allington DR, CochranGA, Colucci VJ, Rivey MP, Williams AK. Student

assessment of program outcomes. Poster presented to AACP Annual Meeting, Toronto, Canada, July 2001.

Rivey MP, Beall HD, Woolley D, Brand P, Ganser A, James W. Investigation of intraarticular

bupivacaine in major orthopedic surgery for postoperative pain control. Poster presented

toAmericanCollege of Clinical Pharmacy Spring Practice and Research Forum, SaltLake

City, UT, April 2001.

Rivey MP. Moderator for Advances in Antithrombotic Therapy session at Montana Society of

Health-Systems Pharmacists (MSHP), West Yellowstone, MT, October 1999.

Messer KG, Rivey MP. Feasibility study for pharmacist-directed asthma management in a

pediatric practice. Poster presented at ACCP/ESCP International Congress on Clinical

Pharmacy, Orlando, FL, April 1999.

Christianson MA, Rivey MP. Evaluation of neonatal gentamicin protocol serum concentration monitoring revision. Poster presented at student research poster session at ASHP Clinical Midyear Meeting, New Orleans, LA, December 1996.

Rivey MP. Moderator for Management Case Studies session at ASHP Clinical Midyear Meeting, New Orleans, LA, December 1996.

Rivey MP. Asthma Care Update. Presented to MSHP Annual Meeting. Technician Session, Billing, Mt. September 1995.

Rivey MP. Patient Care Issues in the Management of Asthma: A Pharmacist's Focus. Presentation to MontanaState Pharmaceutical Assn. Annual Meeting, Helena, Mt. May 1995.

Michael P. Rivey, CVPage 11

Posters/Presentations at National & State Professional Meetings (continued):